Guardant Health, Inc. (GH) is a precision oncology company that sells blood- and tissue-based cancer tests, led by Guardant360 for treatment selection, Reveal for minimal residual disease monitoring and Shield for colorectal cancer screening. Shares traded at $149.41 in midday action, up 2.94% from the previous close of $145.14, confirming an upward move. The gain followed a Buy reiteration and top-pick designation from TD Cowen and commentary from management at an investor healthcare conference, with no new company press release issued on the day.
The clearest verified driver was sell-side support. TD Cowen reaffirmed its Buy rating with a $220 target and placed Guardant among its best ideas for 2027, projecting roughly 35% annual revenue growth over three years and an EBIT margin near 31% by 2030 — a margin trajectory the firm argues the market still underestimates.
That note landed alongside Guardant's fireside chat at the Jefferies Global Healthcare Conference in London, where management pointed to Shield test volumes tripling year over year to 83,000 in the third quarter, cost per test falling to $330 from $410, a submitted application for advanced diagnostic laboratory test status on Guardant360 Liquid CDx, and a reaffirmed target of company-wide free cash flow break-even by the fourth quarter of 2027. Investors have treated that break-even timeline as the central proof point for the story, and management describing it as on track was enough to draw buyers back.
Positioning amplified the move. Guardant closed at $187.22 on October 5 and slid to $143.28 by November 17, a decline of roughly 23%. The selloff accelerated after third-quarter results on November 5: revenue of $361 million rose 36% and beat consensus, and full-year guidance was lifted to $1.36–$1.37 billion, yet shares fell about 9% because the company raised its 2026 free cash flow burn outlook to $205–$220 million from $195–$205 million. A $500 million convertible notes offering priced on November 12 added a dilution overhang. With the stock sitting more than 20% below its October high and near oversold territory, incremental positive commentary was sufficient to trigger a relief rally.
The advance ran against a soft tape. Healthcare was among the weaker sectors, with the sector benchmark down about 1.7%, so Guardant's gain was not a sector-wide sympathy move. Diagnostics peers were mixed: NTRA added roughly 2.4% and NEO rose about 1.4%, while ILMN slipped nearly 2%. Turnover was moderate rather than heavy, tracking close to or below the stock's recent daily pace, which suggests repositioning by existing holders rather than a wave of new institutional demand. Technically, shares opened at $148.50, pushed to $155.97, then faded back toward $149, remaining below the 50-day moving average near $167 while holding well above the 200-day average around $133.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 20 out of 100.
The verified news was moderate at best: a reiterated rating with an unchanged target and a conference appearance, material for sentiment but not a change in fundamentals. The price move was also unremarkable by this stock's standards — 2.94% against a typical daily swing of about 2.3% over the past 60 sessions, or roughly 1.3 times normal, with 20 sessions in that window producing equal or larger moves. Limited news and ordinary volatility combine into a low score.
Attention turns to the Piper Sandler healthcare conference on December 1, where management may update progress on commercial payer contracting for Shield. The next hard catalyst is fourth-quarter and full-year 2026 results, expected around February 18, 2027, when investors will test whether Shield volumes clear 90,000 and whether revenue per test holds above the $700 floor as commercially insured patients become a larger share of the mix. A pending advanced diagnostic laboratory test designation for Guardant360 Liquid CDx, expected in the first half of 2027, is the key pricing lever for the oncology franchise, while the clinical launch of Reveal Ultra is slated before year-end. Risks include persistent cash burn, an appeal in the TwinStrand patent dispute, rising competition in colorectal screening from Abbott's newly approved blood test, and the slow timeline for an updated federal screening guideline.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the lineup shifts as market conditions change. Investors seeking systematic exposure rather than discretionary calls may find the ranked list a useful starting point for further review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GH moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend. In 30 of 33 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GH as a result. In 67 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for GH turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 33 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
The 10-day moving average for GH crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
GH broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GH entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GH's RSI Indicator exited the oversold zone, 23 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in 244 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-90.844) is normal, around the industry mean (67.298). P/E Ratio (-42.983) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of diagnostic technologies to improve cancer management
Industry MedicalSpecialties